Abstract
6
weight and the expected 1% gain in weight per day after day 8
15 . The distribution of the 114 gestational ages of true negatives was derived from reference values published annually in 115
France (DRESS 2001) . 116 We searched for false negatives (FN) detected before March 2010, which is at least six 117 years after the birth of the last child studied, using five data sources: 1) regional screening 118 centres notified of FN cases by physicians; 2) mail and e-mail surveys of all paediatric 119 endocrinologists registered with the national society or treating children with CAH; 3) the 120
French reference centre for CAH genotyping in Lyon and another molecular biology 121 laboratory performing CAH genotyping and 4) the Centre for Epidemiology Medical Causes 122 of Death database (CépiDc, INSERM) , in which we looked for children dying from causes 123 corresponding to International Classification of Diseases (ICD) 9 and 10 codes 255.2, 255.4, 124
E25, E27.4 (adrenogenital disorders, other and unspecified adrenocortical insufficiency). 125

Statistical analysis
126
We calculated the sensitivity, specificity and predictive values of the screening test, 127 with 95% confidence intervals (CI) for preterm neonates born before 37 weeks of gestational 128 age, for term newborns, and for both considered together. We classified the contribution of 129 CAH screening to the diagnosis of true positives as follows: screening was considered useful 130 if it led to the diagnosis of classical 21OHD (SW or SV forms) or 3ß-HSD deficiency that was 131 not suspected clinically because there were no symptoms or because the symptoms and signs 132 (genital abnormalities, dehydration) had not been recognised; screening was considered not 133 useful if CAH was diagnosed before the results of screening became available (on the basis of 134 family history, prenatal diagnosis or neonatal systematic examination). Screening was also 135 considered not useful for false negative cases of classical CAH and for children with positive 136 screening results diagnosed with non-classical forms of CAH.
7
The relationship between gestational age at birth and 17-OHP concentration was 138 studied by linear regression analysis in a sample of 10,523 preterm neonates born before 37 139 weeks of amenorrhoea selected from the infants testing positive. The values for 17-OHP 140 concentration were not normally distributed and a natural logarithm transformation was 141 therefore applied. Goodness of fit (R 2 ) was calculated for various linear regression models, to 142 identify the factor best predicting 17-OHP concentration: gestational age or birth weight. 143
Linear regression models were constructed for the imputation of missing data for term or birth 144 weight. 145
Mortality rates for children under the age of one year were calculated between 1979 146 and 2007, from CepiDc data. Changes in mortality rate over time were assessed by Poisson 147 regression analysis. We looked for a possible change in slope after 1996 (the year in which 148 the screening programme was generalised), by looking for an interaction between "year", 149 considered as a continuous variable, and "before/after screening introduction" considered as a 150 dichotomous variable. 151
All analyses were performed with SAS 9.2 software (SAS Institute, Cary, NC, USA). 152
The study was approved by the CCTIRS and CNIL and was conducted in accordance with 153 French legislation. 154 155 8
Results
156
During the eight-year study period, 6,012,798 screening tests for 21OHD were 157 performed on children born in mainland France ( Figure 1 , Table 1 and supplementary Table  158 1). The laboratory methods for 17-OHP determinations and their thresholds are shown in 159 supplementary Table 1 . Neonatal screening tests were positive for 15,407 newborns, with 160 370 considered affected, 11,324 considered unaffected and no conclusion reached by the 161 screening centres for 3,132. For 1,814 infants, the conclusion was discordant with the last 162 recorded 17-OHP concentration (n = 338 considered unaffected with a last 17-OHP 163 determination considered positive and n = 1476 considered unaffected without the recorded 164 monitoring of 17-OHP concentrations). 581 children were identified as deceased : most of 165 these children were preterm and, in all cases, the death of the child was considered by clinical 166 centres to be unrelated to 21OHD (Figure 1) . Most of the newborns with positive results for 167 21OHD screening were born before term (91% of those for whom data were available). The 168 median day for filter paper sampling was day 4, although the screening protocol called for 169 sampling on day 3. Of the 370 newborns considered to be affected, 358 had a classical form 170 of 21OHD (n = 354) or 3βHSD (n = 4) deficiency and 12 had a non-classical form of CAH. 171
The median age at diagnosis of CAH was seven days (Table 2) and 2003, this study is by far the largest to date to assess neonatal screening for 21OHD with 212 particular emphasis on its contribution to early diagnosis. We found that sensitivity was good 213 (93%), but that the positive predictive value of screening was low (2.3%), although it 214 improved markedly if we considered only term newborns (30.4%). Screening results 215 contributed to diagnosis in 42% of the cases. Moreover, the large number of infants for which 216 no conclusion was drawn raises questions about the practical organisation of 21OHD 217 screening, due to the large number of false positives. 218 Table 4 summarises published data from previous population studies, making 219 comparisons with our results possible. The positive predictive values reported in these studies 220 were similar in most cases, with the exception of the Swiss study (positive predictive value of 221 50%), which presented results for a second determination of 17-OHP on filter paper, rather 222 than those for the primary screening, as in most studies. Unlike previous studies, we took 223 gestational age into account, and we found that screening efficiency differed considerably 224 between term and preterm newborns. Among preterm newborns, there were almost 277 false 225 positives for each case of 21OHD discovered, whereas there were only two to three false 226 positives for each case for term newborns. These difficulties arise from the low specificity of 227 immunological assay techniques for determining levels of 17-OHP in preterm newborns due 228 to high plasma concentrations of steroids other than 17-OHP that cross-react in the assays 229 (with sulphated metabolites), generating false-positive results [16] [17] [18] . Some countries have 230 adopted variable threshold values based on gestational age (Table 4 ), but our study shows that 231 there is a large overlap of 17-OHP levels between affected and unaffected preterm newborns 232 and that increasing the threshold level in this particular population would result in a loss of 233 sensitivity. One possible alternative is the use of tandem mass spectrometry as a second line 234 12 test to improve the positive predictive value of screening 10, 19 . These techniques were recently 235 recommended in the Endocrine Society guidelines 3 , but they are costly, not widely available 236
for population screening and require thorough evaluation, including cost-benefit analyses. Screening for 21OHD is designed principally to decrease neonatal disease-specific 247 mortality. A decrease in specific mortality has been observed over the last three decades, but 248 the timing of this decrease suggests that it was due to improvements in paediatric care rather 249 than to the introduction of screening. The probability of death due to neonatal adrenal crisis 250 in the absence of screening is widely debated and has been reported to vary from 0 to 4% of 251 patients with SW 21OHD in populations with high standards of clinical awareness and care 252 for 21OHD 7 . In our study population of 285 children with salt-wasting 21OHD born 253 between 1996 and 2003 (276 true positives and 9 false negatives), using 4% as an estimate 254 suggests that 11.5 neonatal deaths would have been expected in the absence of screening, a 255 figure to compare to 3 deaths observed during the first year of life. In addition to preventing 256 mortality, screening for 21OHD can prevent inaccurate gender assignment and irreversible 257 childhood hyperandrogenism. In our study, inaccurate gender assignment was not made in 258 the 5 fully virilised females (Prader stage V) but screening allowed the identification of 47/77 259 13 patients with a SV form confirming the value of screening to detect the 21OHD before the 260 appearance of severe hyperandrogenism. 261
Our findings also show that the organisation of screening, as currently conducted in 262
France (and possibly elsewhere), was not satisfactory. Screening centres encountered major 263 operational difficulties with follow-up of the large number of positive tests and no conclusion 264 about status was reached in many cases, raising medical, ethical and responsibility issues. 265
Questions remain concerning the fate of 307 children for whom successive assays remained 266 above the threshold value but for whom no further follow-up data were obtained. Data for 267 weight and gestational age were also frequently missing, although this information makes it 268 easier to interpret the assay results and should therefore be collected. 269
Our study was subject to several limitations. The apparent lack of impact of screening 270 on mortality is likely due to insufficient statistical power, given the limited numbers in the 271 mortality analysis (21 deaths in 29 years), the unmeasured effect of pilot 21OHD screening 272 programs during the 1990-1995 period and more importantly undiagnosed 21OHD-related 273 deaths in the period before screening as documented in central Europe 20 . In addition, 274 inclusion in our analysis of misclassified adrenal diseases other than CAH might have 275 obscured the effect of screening on mortality. However, the study had sufficient power (80%) 276 to detect a decrease in specific mortality of 65% or more after screening implementation. We 277 could not trace with precision the reasons for which false-negative cases were missed (17-278 OHP concentration below the threshold, positive test not taken into account correctly, other 279 reason). False-negative cases may have been underestimated for several reasons, including 280 lack of ascertainment if cases were detected later in life and not followed by paediatric 281 endocrinologists or subjected to molecular analyses. We were also unable to determine the 282 number of unnecessary visits and laboratory investigations for children eventually found not 283 to have 21OHD, or their impact on the anxiety of the parents. Missing data on gestational age 284 14 may have resulted in an overestimation of the sensitivity of the screening, particularly in 285 subgroup analysis (preterm and term newborns). One further limitation is that data on 286 neonatal screening from 1996-2003 are only presented in 2011, at a time when they might be 287 considered less timely. This apparent delay results from long and tedious data collection and 288 monitoring and from the need to wait several years in order to be able to identify FN SV 289 forms since the diagnosis is made as late as 5 or 6 years in some cases. Indeed, we searched 290 for FN cases in 2010, at a time when the youngest child in the cohort was older than 6 years, 291 which is an additional strength of our study. 292
In France, the budget per screened infant (for 21-OHD only) is €1.23 in the absence of 293 follow-up (US$ 1.7), corresponding to approximately €924,500/year. As ≈ 20 cases of 294 21OHD are identified by screening each year, this budget corresponds to approximately 295 €50,000 (US$ 70,000) per case. In the US, the cost per screened infant without follow-up has 296 been estimated at US$ 2.3 to 6.0 and applying these figures to our data would result in 297 estimates of US$ 95,000 to 245,000 per case 21 . Assumptions concerning the number of 298 potential deaths among these cases and a complete medical economic analysis of indirect 299 costs might allow a full evaluation of the cost per life-year saved 21 . 300
Overall, we found that neonatal 21OHD screening was efficient in term newborns, 301 with a variable impact on clinical management given that most affected female newborns are 302 easy to identify without screening. By contrast, the efficiency of screening was very low in 303 preterm newborns, resulting in large numbers of false positives, flooding the system and 304 leading to its dysfunction and leading to the identification of 6 cases of potentially lethal salt-305 wasting 21OHD among more than 10,000 positives in 8 years. Improved organisation might 306 have prevented this dysfunction and allowed a comprehensive follow-up of all positive cases. 307
However, a decrease of the false positive cases is necessary to improve efficiency. 308
15 So, what recommendations should be made based on our results? We recommend that 309 newborn screening for 21OHD is continued for term newborns in areas in which it is already 310 performed and that careful consideration is given to its implementation in areas in which this 311 is not the case. By contrast, we recommend that 21OHD screening, as performed in this 312 study, should not be carried out for preterm newborns since the positive predictive value of 313 the test is very low and most preterm newborns are subject to careful paediatric care that 314 should ensure that incipient salt wasting adrenal crises are readily recognised. In France, the 315 national neonatal screening organisation and representatives of professional organisations in 316 neonatology, paediatric endocrinology and rare endocrine diseases are currently discussing 317 how to improve the national screening program. Our improved program, as well as others 318
around the world will have to be carefully evaluated. 
